Analyst Ratings Network logo

NASDAQ:TRUP - Trupanion Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $62.60
  • Forecasted Upside: -46.70 %
  • Number of Analysts: 7
  • Breakdown:
  • 0 Sell Ratings
  • 4 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$117.45 As of 01/15/2021 01:00 AM ET
▼ -4.22 (-3.47%)
1 month | 3 months | 12 months
Get New Trupanion Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for TRUP and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for TRUP

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$62.60
▼ -46.70% Downside Potential
This price target is based on 7 analysts offering 12 month price targets for Trupanion in the last 3 months. The average price target is $62.60, with a high forecast of $95.00 and a low forecast of $40.00. The average price target represents a -46.70% upside from the last price of $117.45.
Hold
The current consensus among 7 investment analysts is to hold stock in Trupanion. This rating has held steady since September 2019, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 5 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
7/25/2019
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
10/23/2019
  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
1/21/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 5 hold ratings
  • 0 sell ratings
Ratings as of
4/20/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 5 hold ratings
  • 0 sell ratings
Ratings as of
7/19/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
10/17/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
12/16/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
1/15/2021

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 4 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/2/2020Canaccord GenuityBoost Price TargetBuy$88.00 ➝ $95.00High
i
10/30/2020Lake Street CapitalBoost Price Target$67.00 ➝ $85.00High
i
Rating by Mark Argento at Lake Street Capital
8/10/2020GuggenheimDowngradeBuy ➝ NeutralLow
i
8/5/2020Canaccord GenuityBoost Price TargetBuy$58.00 ➝ $62.00High
i
8/5/2020Lake Street CapitalBoost Price TargetPositive ➝ Buy$50.00 ➝ $67.00High
i
Rating by Mark Argento at Lake Street Capital
8/5/2020Northland SecuritiesDowngradeOutperform ➝ Market Perform$42.00 ➝ $50.00High
i
Rating by Greg Gibas at Northland Securities
7/30/2020Stifel NicolausBoost Price TargetHold$33.00 ➝ $43.00Low
i
6/25/2020Northland SecuritiesInitiated CoverageBuy$42.00Medium
i
Rating by Greg Gibas at Northland Securities
6/15/2020Royal Bank of CanadaReiterated RatingBuy$40.00High
i
6/9/2020Northland SecuritiesInitiated CoverageBuy$42.00Low
i
Rating by Greg Gibas at Northland Securities
5/1/2020Lake Street CapitalReiterated RatingBuy$50.00Low
i
Rating by Mark Argento at Lake Street Capital
5/1/2020Royal Bank of CanadaBoost Price TargetOutperform$39.00 ➝ $40.00High
i
5/1/2020Northland SecuritiesReiterated RatingBuy$35.00High
i
4/27/2020Royal Bank of CanadaReiterated RatingBuy$39.00High
i
4/8/2020Royal Bank of CanadaReiterated RatingBuy$39.00High
i
4/6/2020Northland SecuritiesReiterated RatingBuy$35.00High
i
3/2/2020Canaccord GenuityReiterated RatingBuy$44.00High
i
2/14/2020Lake Street CapitalBoost Price TargetBuy$46.00 ➝ $50.00Low
i
2/14/2020Canaccord GenuityReiterated RatingBuy$44.00High
i
2/14/2020Raymond JamesDowngradeOutperform ➝ Market PerformHigh
i
1/8/2020Stifel NicolausDowngradeBuy ➝ Hold$32.00 ➝ $38.00High
i
11/18/2019GuggenheimBoost Price TargetBuy$35.00 ➝ $36.00Low
i
Rating by David Westenberg at Guggenheim
11/6/2019Northland SecuritiesReiterated RatingBuy$40.00High
i
Rating by Greg Gibas at Northland Securities
10/11/2019Craig HallumSet Price TargetHold$20.00Low
i
Rating by Kevin Ellich at Craig Hallum
8/16/2019Craig HallumDowngradeBuy ➝ Hold$29.00High
i
7/31/2019Royal Bank of CanadaSet Price TargetBuy$38.00Low
i
Rating by Mark Mahaney at Royal Bank of Canada
7/31/2019Northland SecuritiesReiterated RatingBuy$40.00High
i
Rating by Greg Gibas at Northland Securities
5/23/2019GuggenheimInitiated CoverageBuy ➝ Buy$35.00High
i
5/14/2019Northland SecuritiesInitiated CoverageBuy$40.00High
i
11/13/2018Canaccord GenuityReiterated RatingBuy$43.00High
i
10/2/2018CL KingUpgradeNeutral ➝ BuyLow
i
9/6/2018Raymond JamesInitiated CoverageOutperform ➝ Outperform$46.00High
i
8/3/2018Lake Street CapitalReiterated RatingBuy$41.00 ➝ $46.00Medium
i
8/3/2018CowenBoost Price TargetOutperform ➝ Positive$41.00 ➝ $47.00Medium
i
8/3/2018Royal Bank of CanadaBoost Price TargetOutperform$44.00Medium
i
8/3/2018Stifel NicolausBoost Price TargetBuy ➝ Buy$40.00 ➝ $43.00Medium
i
8/3/2018Canaccord GenuityBoost Price TargetBuy ➝ Buy$40.00 ➝ $46.00Medium
i
7/19/2018Craig HallumInitiated CoverageBuy$55.00High
i
7/10/2018Stifel NicolausBoost Price TargetBuy ➝ Buy$34.00 ➝ $40.00Low
i
5/2/2018Canaccord GenuityReiterated RatingBuy$40.00Medium
i
2/14/2018Lake Street CapitalBoost Price TargetBuy ➝ Buy$32.00 ➝ $41.00High
i
2/14/2018CowenReiterated RatingOutperform$32.00 ➝ $38.00High
i
2/14/2018Stifel NicolausReiterated RatingBuy ➝ Buy$33.00 ➝ $34.00High
i
2/8/2018Northland SecuritiesReiterated RatingBuy$38.00High
i
11/21/2017CL KingInitiated CoverageNeutralN/A
i
10/31/2017Canaccord GenuityReiterated RatingBuy$29.00 ➝ $35.00N/A
i
8/2/2017Canaccord GenuityBoost Price TargetBuy$28.00 ➝ $29.00Medium
i
8/2/2017CowenReiterated RatingOutperform$19.00 ➝ $28.00High
i
8/2/2017Stifel NicolausReiterated RatingBuy ➝ Buy$18.00 ➝ $24.00High
i
8/2/2017Royal Bank of CanadaBoost Price TargetOutperform ➝ Outperform$19.00 ➝ $26.00High
i
7/14/2017CowenReiterated RatingBuy$19.00Low
i
7/6/2017Northland SecuritiesSet Price TargetBuy$23.00Low
i
5/26/2017Northland SecuritiesInitiated CoverageOutperform ➝ Outperform$22.75High
i
11/3/2016Royal Bank of CanadaReiterated RatingBuy$18.00N/A
i
9/20/2016Royal Bank of CanadaSet Price TargetBuy$18.00N/A
i
8/4/2016Canaccord GenuityReiterated RatingBuy$19.00N/A
i
8/3/2016Royal Bank of CanadaReiterated RatingOutperform$14.00 ➝ $18.00N/A
i
8/3/2016Stifel NicolausBoost Price TargetBuy$17.00 ➝ $20.00N/A
i
7/19/2016Lake Street CapitalInitiated CoverageBuy$18.00N/A
i
Rating by M. Argento at Lake Street Capital
5/9/2016BarclaysLower Price TargetEqual Weight$14.00 ➝ $9.00N/A
i
5/6/2016Royal Bank of CanadaBoost Price TargetOutperform$12.00 ➝ $14.00N/A
i
5/4/2016Stifel NicolausBoost Price TargetBuy$16.00 ➝ $17.00N/A
i
5/4/2016Royal Bank of CanadaReiterated RatingBuy$12.00N/A
i
3/1/2016CowenBoost Price TargetOutperform$9.00 ➝ $11.00N/A
i
2/12/2016Canaccord GenuityReiterated RatingBuy$12.00N/A
i
Rating by Michael Graham at Canaccord Genuity
2/10/2016Royal Bank of CanadaReiterated RatingOutperform$12.00N/A
i
Rating by Rohit Kulkarni at Royal Bank of Canada
(Data available from 1/16/2016 forward)
Trupanion logo
Trupanion, Inc., together with its subsidiaries, provides medical insurance for cats and dogs on monthly subscription basis in the United States, Canada, and Puerto Rico. The company operates through Subscription Business and Other Business segments. It serves pet owners and veterinarians through third-party referrals and online member acquisition channels. The company was formerly known as Vetinsurance International, Inc. changed its name to Trupanion, Inc. in 2013. Trupanion, Inc. was founded in 2000 and is headquartered in Seattle, Washington.
Read More

Today's Range

Now: $117.45
$115.24
$122.94

50 Day Range

MA: $111.01
$94.05
$122.08

52 Week Range

Now: $117.45
$22.48
$124.73

Volume

309,178 shs

Average Volume

411,786 shs

Market Capitalization

$4.18 billion

P/E Ratio

2,349.47

Dividend Yield

N/A

Beta

1.54

Frequently Asked Questions

What sell-side analysts currently cover shares of Trupanion?

The following Wall Street sell-side analysts have issued research reports on Trupanion in the last twelve months: Canaccord Genuity, Guggenheim, Lake Street Capital, Northland Securities, Raymond James, Royal Bank of Canada, Stifel Nicolaus, and Zacks Investment Research.

What is the current price target for Trupanion?

5 Wall Street analysts have set twelve-month price targets for Trupanion in the last year. Their average twelve-month price target is $62.60, suggesting a possible downside of 46.7%. Canaccord Genuity has the highest price target set, predicting TRUP will reach $95.00 in the next twelve months. Royal Bank of Canada has the lowest price target set, forecasting a price of $40.00 for Trupanion in the next year.

What is the current consensus analyst rating for Trupanion?

Trupanion currently has 4 hold ratings and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in TRUP, but not buy more shares or sell existing shares.

What other companies compete with Trupanion?

Other companies that are similar to Trupanion include UnitedHealth Group, Anthem, Cigna, Humana, Centene, Molina Healthcare, Clover Health Investments and Advanzeon Solutions.

How do I contact Trupanion's investor relations team?

Trupanion's physical mailing address is 6100 4TH AVENUE SOUTH SUITE 200, SEATTLE WA, 98108. The financial services provider's listed phone number is 855-727-9079 and its investor relations email address is investorrelations@trupanion.com. The official website for Trupanion is www.trupanion.com.